Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

16.46 -2.02 (-10.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Beam Therapeutics Named to Boston Globe’s Top Places to Work List for 2022
Beam Ranked No. 4 in Large Companies Category, Marking Fourth Consecutive Year as Top Workplace in Massachusetts 
From Beam Therapeutics
Via GlobeNewswire
BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts
Although US stocks closed mixed on Thursday, but healthcare stocks recorded gains, gaining over 0.2% in the previous session. Biotechnology stocks were among the top performers in the sector, adding... 
Via Benzinga
Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for BEAM-201
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics's Return On Capital Employed Insights
Via Benzinga
Beam Therapeutics Temporarily Retreats Clinical Plans For Second Sickle Cell Gene Therapy
Via Benzinga
Why Beam Therapeutics Stock Is Falling Today
Beam's decision not to move forward with sickle cell treatment BEAM-102 isn't sitting well with investors today. 
Via The Motley Fool
Beam Therapeutics to Participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference
From Beam Therapeutics
Via GlobeNewswire
A Sitcom Character Inspired This Investor
Plus, a look at the "Buffett premium" that investors give to Berkshire Hathaway stock. 
Via The Motley Fool
Beam Therapeutics Enrolls First Patient in BEACON Clinical Trial of BEAM-101 Base Editing Therapy Candidate for the Treatment of Sickle Cell Disease
BEAM-101 BEACON Trial Represents the First Clinical Trial of a Base Editor in the United States 
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics: Q3 Earnings Insights
Beam Therapeutics (NASDAQ:BEAM) reported its Q3 earnings results on Monday, November 7, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Recap: Beam Therapeutics Q2 Earnings
  Beam Therapeutics (NASDAQ:BEAM) reported its Q2 earnings results on Tuesday, August 9, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Unity Software, Amazon, Doximity And Other Big Gainers From Friday
U.S. stocks closed higher on Friday, with the Nasdaq Composite jumping more than 200 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Beam Therapeutics to Participate in Upcoming Investor Conferences
From Beam Therapeutics
Via GlobeNewswire
TreeHouse Foods, Ritchie Bros. Auctioneers, Beam Therapeutics And Some Other Big Stocks Moving Lower On Monday
U.S. stocks traded mostly higher, with the Dow Jones gaining more than 150 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Why Beam Therapeutics Stock Is Falling Today
Beam Therapeutics Inc (NASDAQ: BEAM) shares are trading lower Monday after the company reported earnings results that were down year-over-year. 
Via Benzinga
Why Oyster Point Pharma Shares Are Trading Higher By Around 40%? Here Are 49 Stocks Moving In Monday's Mid-Day Session
Gainers Dragon Victory International Limited (NASDAQ: LYL) surged 52.2% to $0.6870. 
Via Benzinga
Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Present New Preclinical Data Highlighting Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant at the 64th ASH Annual Meeting
From Beam Therapeutics
Via GlobeNewswire
ON Semiconductor, Global Payments And Other Big Losers From Monday
U.S. stocks closed lower on Monday, with the Dow Jones dropping more than 100 points. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
Despite enthusiasm in some camps, the risk of potential cures clouds market projections. 
Via Investor's Business Daily
Beam Therapeutics Touts Encouraging Preclinical Data From Gene Editing Approach For Hepatitis B Infection
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Apple, Amazon, HP And Other Big Losers From Friday
U.S. stocks closed sharply lower with the Dow Jones tumbling more than 1,000 points on Friday. Here is the list of some big stocks moving lower in the previous session. 
Via Benzinga
Why Everbridge Jumped Over 17%; Here Are 90 Biggest Movers From Friday
Gainers Micro Focus International plc (NYSE: MFGP) shares surged 92% to close at $6.01 on Friday after the company reached an agreement with OpenText to be acquired for $6 billion. 
Via Benzinga
Why Minerva Neurosciences Shares Traded Higher By Over 66%; Here Are 78 Biggest Movers From Yesterday
Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) shares gained 66.5% to close at $7.51 after Point72 Asset Management reported an 8.8% passive stake in the company. 
Via Benzinga
5 Cathie Wood Stocks Signaling “The Bear Market Is Over”
These top Cathie Wood stocks are signalling that the bear market is over. For savvy investors, that presents a chance to profit. 
Via InvestorPlace
7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher
These monkeypox stocks could be among the best choices to buy in August. Each can make great investments as government responses ramp up. 
Via InvestorPlace
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
This Technology Stock Jumped 55% Following Q2 Results; Here Are 96 Biggest Movers From Yesterday
Gainers Eargo, Inc. (NASDAQ: EAR) jumped 77.2% to close at $2.02. The FDA finalized rule enabling access to over-the-counter hearing aids. 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.